11 active not recruiting, 7 completed, 7 recruiting, 1 suspended. 20 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Active not recruiting 11, Completed 6, Recruiting 3 |
| Phase 1 | 12 | Recruiting 6, Completed 3, Active not recruiting 1, Suspended 1, Unknown 1 |
Follow Refractory Osteosarcoma: new trials by email Literature Review of Refractory Osteosarcoma trials Research Report on Refractory Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-07-15 | 2026-07-21 |
| Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Tegavivint, Gemcitabine - Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Recruiting | Emory University | 24 | 2026-01-22 | 2026-10-19 |
| Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine - Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-01-16 | 2026-09-01 |
| IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma IM83 CAR-T Cells - Refractory Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 9 | 2024-06-15 | 2024-05-14 |
| Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate - Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Emory University | 24 | 2023-11-06 | 2025-12-26 |
| Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study Atezolizumab, Cabozantinib - Locally Advanced Osteosarcoma, Metastatic Osteosarcoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2023-04-25 | 2026-10-06 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 73 | 2022-01-25 | 2026-08-05 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Cabozantinib With Topotecan-Cyclophosphamide Cabozantinib, Topotecan, Cyclophosphamide - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2020-12-23 | 2023-02-15 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-06-22 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Docetaxel, Gemcitabine, Hydroxychloroquine - Recurrent Osteosarcoma, Refractory Osteosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2019-01-28 | 2026-05-14 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
Showing 20 of 27. Sign in to see all of them.
Osteosarcoma (27) · Neuroblastoma (16) · Hepatoblastoma (13) · Rhabdomyosarcoma (13) · Sarcoma (13) · Wilms Tumor (13) · Lymphoma, Non-Hodgkin (12) · Neuroectodermal Tumors, Primitive, Peripheral (12) · Rhabdoid Tumor (11) · Sarcoma, Ewing (11) · Ependymoma (10) · Glioma (10) · Histiocytosis, Langerhans-Cell (10) · Medulloblastoma (10) · Central Nervous System Neoplasms (6)
Neoplasms by Histologic Type (27) · Neoplasms, Bone Tissue (27) · Neoplasms, Connective Tissue (27) · Neoplasms, Connective and Soft Tissue (27) · Neoplasms (26) · Neoplasms, Glandular and Epithelial (18) · Neoplasms, Germ Cell and Embryonal (17) · Neoplasms, Nerve Tissue (17) · Neuroectodermal Tumors (17) · Neoplasms, Neuroepithelial (16) · Neuroectodermal Tumors, Primitive (16) · Neoplasms by Site (15) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Sarcoma (14)
X-Rays (6) · Biopsy (5) · Magnetic Resonance Spectroscopy (5) · Phantoms, Imaging (5) · Specimen Handling (5) · Cyclophosphamide (4) · Nuclear Medicine Department, Hospital (4) · cabozantinib (3) · CTLA-4 Antigen (2) · Gemcitabine (2) · Ipilimumab (2) · Nivolumab (2) · Temozolomide (2) · ensartinib (2) · fludarabine (2)
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (4) · Children's Oncology Group (3) · Emory University (2) · Baylor College of Medicine (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · Fred Hutchinson Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (26) · Puerto Rico (11) · Canada (5) · Australia (4) · China (1)
Katherine A Janeway (2) · Amir A Jazaeri (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Crystal L Mackall (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Emily G Greengard (1) · John A Livingston (1) · John A Livingston, MD (1) · Julia Glade-Bender (1) · Kelly Goldsmith, MD (1) · Kieuhoa T Vo (1) · Leander D Timothy, MD (1) · Meredith S Irwin (1)
PMID 31401903, PMID 32192573, PMID 33591402, PMID 34486544, PMID 35353553, PMID 38520670, PMID 38815151, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (12), UM1CA097452 (2), UM1CA228823 (2), P30CA016672 (1), U24CA224309 (1), UM1CA154967 (1)